ProPhase Labs Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ProPhase Labs stock.
View analyst ratings for ProPhase Labs or view top-rated stocks.

Wall Street analysts have given ProPhase Labs a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ProPhase Labs wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

ProPhase Labs is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for ProPhase Labs.

ProPhase Labs, Inc. (NASDAQ:PRPH) released its earnings results on Thursday, May, 13th. The company reported $0.23 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.35 by $0.12. The business earned $15.27 million during the quarter, compared to analysts' expectations of $11.23 million. ProPhase Labs had a negative net margin of 0.93% and a positive trailing twelve-month return on equity of 12.01%.
View ProPhase Labs' earnings history.

ProPhase Labs' stock was trading at $2.0301 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRPH stock has increased by 179.3% and is now trading at $5.67.
View which stocks have been most impacted by COVID-19.

ProPhase Labs announced a dividend on Thursday, May 13th. Shareholders of record on Tuesday, May 25th will be paid a dividend of $0.30 per share on Thursday, June 3rd. The ex-dividend date is Monday, May 24th. This is an increase from ProPhase Labs's previous dividend of $0.25.
View ProPhase Labs' dividend history.

1 analysts have issued 12 month price objectives for ProPhase Labs' shares. Their forecasts range from $25.00 to $25.00. On average, they anticipate ProPhase Labs' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 340.9% from the stock's current price.
View analysts' price targets for ProPhase Labs or view top-rated stocks among Wall Street analysts.

2 employees have rated ProPhase Labs CEO Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among ProPhase Labs' employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to ProPhase Labs include XOMA (XOMA), Immutep (IMMP), NexImmune (NEXI), 9 Meters Biopharma (NMTR), Adicet Bio (ACET), Frequency Therapeutics (FREQ), iBio (IBIO), Athersys (ATHX), CymaBay Therapeutics (CBAY), RedHill Biopharma (RDHL), Verrica Pharmaceuticals (VRCA), Aeglea BioTherapeutics (AGLE), Syros Pharmaceuticals (SYRS), Trevena (TRVN) and Arbutus Biopharma (ABUS).
View all of PRPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH).

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

ProPhase Labs' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.92%), Wedge Capital Management L L P NC (0.79%), Kamunting Street Capital Management L.P. (0.65%), Bank of New York Mellon Corp (0.60%), Geode Capital Management LLC (0.54%) and Acadian Asset Management LLC (0.40%). Company insiders that own ProPhase Labs stock include Jason Michael Barr, Louis Md Gleckel and Ted William Karkus.
View institutional ownership trends for ProPhase Labs.

PRPH stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp.
View insider buying and selling activity for ProPhase Labs or view top insider-selling stocks.

PRPH stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Kamunting Street Capital Management L.P., Bank of New York Mellon Corp, Acadian Asset Management LLC, FNY Investment Advisers LLC, Geode Capital Management LLC, Dimensional Fund Advisors LP, and Perritt Capital Management Inc.. Company insiders that have bought ProPhase Labs stock in the last two years include Jason Michael Barr, and Louis Md Gleckel.
View insider buying and selling activity for ProPhase Labs or or view top insider-buying stocks.

Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRPH stock can currently be purchased for approximately $5.67.

ProPhase Labs has a market capitalization of $85.92 million and generates $14.51 million in revenue each year. The company earns $-2,130,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis.

ProPhase Labs employs 95 workers across the globe.

The official website for ProPhase Labs is www.prophaselabs.com.

ProPhase Labs is headquartered at 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901.

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company can be reached via phone at 215-345-0919 or via email at [email protected]